## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

# CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 18, 2018

### SCYNEXIS, Inc.

(Exact name of registrant as specified in its charter)

	Delaware	001-36365	56-2181648
	(State or other jurisdiction	(Commission	(IRS Employer
	of incorporation)	File Number)	Identification No.)
1 Evertrust Plaza, 13th Floor  Jersey City, New Jersey 07302-6548 (Address of principal executive offices, including zip code)  (201)-884-5485 (Registrant's telephone number, including area code)			
	(For	N/A mer name or former address, if changed since last rep	ort)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:			
	Written communications pursuant to F	Rule 425 under the Securities Act (17 CFR 230.42	25)
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
	Pre-commencement communications p	oursuant to Rule 13e-4(c) under the Exchange Ac	t (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  $\boxtimes$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\boxtimes$ 

### Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 18, 2018, Marion McCourt provided SCYNEXIS, Inc. with notice of her resignation from the Board of Directors (the "Board"), effective immediately, due to the time commitments associated with her ongoing responsibilities as Senior Vice President and Head of Commercial at Regeneron Pharmaceuticals, Inc. Ms. McCourt had served on the Board since 2017.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCYNEXIS, Inc.

Dated: September 21, 2018 By: /s/ Eric Francois

Eric Francois

Chief Financial Officer